Results 131 to 140 of about 2,004 (157)

Ravulizumab

Reactions Weekly
  +5 more sources

Eculizumab/ravulizumab

Reactions Weekly, 2023
openaire   +1 more source

Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis

Journal of Neurology, 2023
Djillali Annane, Masahisa Katsuno, James F Howard   +2 more
exaly  

Ravulizumab effective in AQP4+ NMOSD

Medicom Conference Report AAN 2023, 2023
openaire   +1 more source

Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies

British Journal of Haematology, 2020
Peter Hillmen, Robert Brodsky
exaly  

Mycophenolate-mofetil/ravulizumab/steroids

Reactions Weekly, 2023
openaire   +1 more source

Non-capsulated Neisseria meningitidis sepsis in a paroxysmal nocturnal hemoglobinuria patient treated with ravulizumab: case report and review of the literature

Frontiers in Immunology, 2023
Bruno Fattizzo, Wilma Barcellini, Barcellini Wilma   +2 more
exaly  

Ravulizumab in patients with generalised myasthenia gravis

Medicom Conference Report AAN 2022, 2022
Tuan Hoang Vu, Michiel Tent
openaire   +1 more source

Impact of Ravulizumab on Patient Outcomes and Quality of Life in Generalized Myasthenia Gravis

Patient Related Outcome Measures, 2023
Carlo Antozzi, Renato Mantegazza
exaly  

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Kidney International, 2020
Garrouste Cyril, Spero Cataland, Maria Cappuccilli   +2 more
exaly